New Diagnostic Strategy for Multiple Myeloma: A Review
Overview
Affiliations
Multiple myeloma (MM) is the second most prevalent hematological malignancy and is distinguished by the aberrant proliferation of monoclonal plasma cells inside the bone marrow and production of M-protein. This condition frequently results in bone deterioration, acute kidney damage, anemia, and hypercalcemia. However, the clinical manifestations and accompanying symptoms of MM vary and may change as the condition evolves. Therefore, diagnosis of MM is difficult. At present, the confirmation of MM diagnosis necessitates the use of bone marrow biopsy, a procedure that is both invasive and challenging for assessing dynamic alterations in the disease. The integration of laboratory testing technologies with imaging technology has the potential to enhance the diagnostic effectiveness and provide a thorough evaluation of disease progression and prognosis in patients with MM. All the examination methods have advantages and disadvantages. Therefore, diagnosis is determined by the application of clinical characteristics, serological tests, and imaging investigations.
miR‑1343‑3p inhibits autophagy by directly targeting ATG7 in multiple myeloma cells.
Guo Y, Ding X, Dai C, Wang W, Chen J, Chen S Biomed Rep. 2024; 21(6):185.
PMID: 39420924 PMC: 11484188. DOI: 10.3892/br.2024.1873.
Raghunathachar S, Krishnamurthy K, Gopalaiah L, Abhijith D, Prashant A, Parichay S Mol Biol Rep. 2024; 51(1):972.
PMID: 39249557 DOI: 10.1007/s11033-024-09892-w.
Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma.
Dubaj M, Bigosinski K, Dembowska A, Mlak R, Szudy-Szczyrek A, Malecka-Massalska T Cancers (Basel). 2024; 16(5).
PMID: 38473390 PMC: 10931522. DOI: 10.3390/cancers16051033.